DNM1 and cancer: DNM1 levels were 50 ​% lower among PCD compared to non-PCD cancer patients after exposure to neurotoxic treatment, a difference that is statistically significant (RC ​= ​0.50, 95 ​% CI ​= ​0.31 to 0.79, P ​= ​0.003), but not among controls (RC ​= ​0.78, 95 ​% CI ​= ​0.49 to 1.24, P ​= ​0.291) (Fig. 1D).